PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-32.96%
Both companies show declining cash positions (-32.96% vs AXSM's -15.60%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-32.96%
Cash + STI yoy ≥ 1.5x AXSM's -15.60%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.20%
≥ 1.5x AXSM's -15.93%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-7.82%
Similar yoy growth to AXSM's -7.48%. Walter Schloss sees parallel capital spending strategies. Check utilization rates.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
305.95%
Below half of AXSM's -3.29%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-28.88%
≥ 1.5x AXSM's -15.88%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-28.35%
Above 1.5x AXSM's -14.81%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.97%
Higher Other Current Liabilities Growth compared to AXSM's zero value, indicating worse performance.
-23.54%
Above 1.5x AXSM's -1.73%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.54%
Above 1.5x AXSM's -4.92%. Michael Burry sees a potential leverage warning sign.
2.39%
Above 1.5x AXSM's 0.30%. Michael Burry suspects heavy new equity expansion or dilution.
-4.88%
Below half AXSM's -12.73%. Michael Burry suspects major net losses or high dividends vs. competitor.
-7.49%
Higher AOCI Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-31.10%
1.25-1.5x AXSM's -22.29%. Bruce Berkowitz notes an above-average equity expansion.
-28.88%
≥ 1.5x AXSM's -15.88%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.96%
Above 1.5x AXSM's 20.31%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.